LainiePMartinMD

Oncology • Philadelphia, PA

Physician

Join to view full profile

Dr. Martin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Martin's full profile

Already have an account?

Office
Perelman Center for Advanced Medicine
3400 Civic Center Blvd
Philadelphia, PA 19104
Phone+1 215-614-1850

Fax+1 215-615-3349

Education & Training

Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
Boston University Medical CenterResidency, Internal Medicine, 1999 - 2002
Lewis Katz School of Medicine at Temple UniversityClass of 1999

Certifications & Licensure

PA State Medical License 2003 - 2024
MA State Medical License 2002 - 2005
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2009 Oct 28
Completed
Phase 1
Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma Start of enrollment: 2009 Nov 01
Completed
Phase 1
Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Oct 01
Completed
Phase 2
Neoadjuvant Therapy for Ovarian Cancer Start of enrollment: 2010 May 17
Completed
Phase 2
Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors Start of enrollment: 2010 Oct 01
Completed
Phase 1, Phase 2
A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer Start of enrollment: 2010 Dec 14
Completed
Phase 1
Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer Start of enrollment: 2012 Dec 03
Completed
Phase 2
A Study of ENMD-2076 in Ovarian Clear Cell Cancers Start of enrollment: 2013 Sep 01
Completed
Phase 2
Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer Start of enrollment: 2013 Sep 30
Completed
Phase 1
Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2013 Oct 09
Terminated
Phase 1, Phase 2
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2014 Jul 21
Active, not recruiting
Phase 2
A Study Comparing AZD-1775 (MK-1775) and Gemcitabine With Gemcitabine Alone in Ovarian, Peritoneal or Fallopian Tube Cancers Start of enrollment: 2014 Jul 01
VM110 in Detection of Microscopic Tumors: A Phase I Study Start of enrollment: 2017 Oct 12
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

Real-world impact of the platinum chemotherapy shortage on US patients with advanced cancer.
Jacob B Reibel, Lova L Sun, Ravi B Parikh, Nadim Mahmud, Lainie P Martin
Journal of the National Cancer Institute. 2024-12-03
NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024.
Joyce Liu, Andrew Berchuck, Floor J Backes, Joshua Cohen, Rachel Grisham
Journal of the National Comprehensive Cancer Network. 2024-10-01
1 citations
Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study.
Charles N Landen, Ronald J Buckanovich, Michael W Sill, Robert S Mannel, Joan L Walker
Journal of Clinical Oncology. 2024-07-20

Journal Articles

Phase Ib Study of Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)-Targeting Antibody-Drug Conjugate (ADC), in Combination with Bevacizumab in Patients with Pl...
David M O'Malley, Ursula A Matulonis, Michael J Birrer, Cesar M Castro, Lainie P Martin, Kathleen N Moore, Gynecologic Oncology

Lectures

Phase I study of carboplatin (C), pegylated liposomal doxorubicin (PLD) and everolimus (E) in platinum-sensitive epithelial ovarian, Fallopian tube or primary peritone...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018